Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone
- PMID: 29339527
- DOI: 10.1530/EJE-17-0673
Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone
Abstract
Aims: One-third of males with type 2 diabetes (T2DM) have hypogonadism, characterized by low total and free testosterone concentrations. We hypothesized that this condition is associated with a compensatory increase in the expression of androgen receptors (AR) and that testosterone replacement reverses these changes. We also measured estrogen receptor and aromatase expression.
Materials and methods: This is a randomized double-blind placebo-controlled trial. Thirty-two hypogonadal and 32 eugonadal men with T2DM were recruited. Hypogonadal men were randomized to receive intramuscular testosterone or saline every 2 weeks for 22 weeks. We measured AR, ERα and aromatase expression in peripheral blood mononuclear cells (MNC), adipose tissue and skeletal muscle in hypogonadal and eugonadal males with T2DM at baseline and after 22 weeks of treatment in those with hypogonadism.
Results: The mRNA expression of AR, ERα (ESR1) and aromatase in adipose tissue from hypogonadal men was significantly lower as compared to eugonadal men, and it increased significantly to levels comparable to those in eugonadal patients with T2DM following testosterone treatment. AR mRNA expression was also significantly lower in MNC from hypogonadal patients compared to eugonadal T2DM patients. Testosterone administration in hypogonadal patients also restored AR mRNA and nuclear extract protein levels from MNC to that in eugonadal patients. In the skeletal muscle, AR mRNA and protein expression are lower in men with hypogonadism. Testosterone treatment restored AR expression levels to that comparable to levels in eugonadal men.
Conclusions: We conclude that, contrary to our hypothesis, the expression of AR, ERα and aromatase is significantly diminished in hypogonadal men as compared to eugonadal men with type 2 diabetes. Following testosterone replacement, there is a reversal of these deficits.
© 2018 European Society of Endocrinology.
Similar articles
-
Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.Diabetes Care. 2016 Jan;39(1):82-91. doi: 10.2337/dc15-1518. Epub 2015 Nov 29. Diabetes Care. 2016. PMID: 26622051 Free PMC article. Clinical Trial.
-
Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men.J Clin Endocrinol Metab. 2005 Feb;90(2):855-63. doi: 10.1210/jc.2004-1577. Epub 2004 Nov 2. J Clin Endocrinol Metab. 2005. PMID: 15522925
-
Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes.Clin Endocrinol (Oxf). 2016 Nov;85(5):772-780. doi: 10.1111/cen.13130. Epub 2016 Jul 18. Clin Endocrinol (Oxf). 2016. PMID: 27292585 Free PMC article. Clinical Trial.
-
Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men.Nat Clin Pract Urol. 2007 Mar;4(3):161-6. doi: 10.1038/ncpuro0706. Nat Clin Pract Urol. 2007. PMID: 17347661 Review.
-
Testosterone Replacement Therapy in Hypogonadal Men.Endocrinol Metab Clin North Am. 2022 Mar;51(1):77-98. doi: 10.1016/j.ecl.2021.11.005. Epub 2022 Feb 8. Endocrinol Metab Clin North Am. 2022. PMID: 35216722 Free PMC article. Review.
Cited by
-
The influence of body composition on the response to dynamic stimulation of the endocrine pituitary-testis axis.Int J Obes (Lond). 2024 Apr 12. doi: 10.1038/s41366-024-01518-2. Online ahead of print. Int J Obes (Lond). 2024. PMID: 38609526
-
Clinical and Therapeutic Implications of Male Obesity.J Clin Med. 2023 Aug 17;12(16):5354. doi: 10.3390/jcm12165354. J Clin Med. 2023. PMID: 37629396 Free PMC article. Review.
-
Association of non-alcoholic fatty liver disease with total testosterone in non-overweight/obese men with type 2 diabetes mellitus.J Endocrinol Invest. 2023 Aug;46(8):1565-1572. doi: 10.1007/s40618-023-02006-6. Epub 2023 Feb 1. J Endocrinol Invest. 2023. PMID: 36725809
-
Hypogonadotropic Hypogonadism in Diabesity: Pathogenic Factors and Therapeutic Implications.Androg Clin Res Ther. 2022 Dec 28;3(1):214-216. doi: 10.1089/andro.2022.0019. eCollection 2022. Androg Clin Res Ther. 2022. PMID: 36643965 Free PMC article. No abstract available.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous